Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth

Journal of Medical Genetics

Volumn 39, Issue 4, 2002, Pages 251-259

  Dean, J C S ^a   Hailey, H ^a   Moore, S J ^b   Lloyd, D J ^c   Turnpenny, P D ^d   Little, J ^e  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c ABERDEEN MATERNITY HOSPITAL   (United Kingdom)

^d ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

ANTICONVULSANT THERAPY; ARTICLE; CHILD; CONGENITAL MALFORMATION; DRUG EFFECT; EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; PRENATAL EXPOSURE; PRIORITY JOURNAL; TERATOGENICITY;

EID: 0036257073     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.39.4.251     Document Type: Article

References (54)

1. Anticonvulsants in pregnancy
2. Teratogenicity of anticonvulsant drugs 1: Review of the literature
3. Congenital malformations due to epileptic drugs
4. Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure
5. Malformations in offspring of 305 epileptic women: A prospective study
6. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort
7. Spina bifida in infants of women treated with carbamazepine during pregnancy
8. The fetal hydantoin syndrome
9. Pattern of malformations in the children of women treated with carbamazepine during pregnancy
10. Consensus guidelines. Preconception counseling, management, and care of the pregnant woman with epilepsy
11. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero
12. A clinical study of 57 children with fetal anticonvulsant syndromes
13. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: Independent effects of epilepsy and medications
14. Neuradevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy
15. Additional educational needs in children born to mothers with epilepsy
16. Psychomotor development and minor anomalies in children exposed to antiepileptic drugs in utero: A prospective population-based study
17. Specific cognitive dysfunction in children with epileptic mothers
18. In utero exposure to phenobarbital and intelligence deficits in adult men
19. Developing diagnostic criteria for the fetal anticonvulsant syndromes
20. Articular mobility in an African population
21. Fetal phenytoin exposure, hypoplastic nails, and jitteriness
22. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy
23. Epilepsy and pregnancy: A report from the Oxford record linkage study
24. In-utero exposure to valproate and neural tube defects
25. Antiepileptic drugs and teratogenesis in two consecutive cohorts
26. Effect of anti-epileptic drugs on intrauterine growth
27. Valproic acid-induced neural tube defects in mouse and human: Aspects of chirality, alternative drug development, pharmakokinetics and possible mechanisms
28. Verification of the fetal valproate syndrome phenotype
29. Antiepileptic drug treatment in pregnancy: Drug side effects in the neonate and neurological outcome
30. Fetal valproate syndrome: Clinical and neuro-developmental features in two sibling pairs
31. A male with fetal valproate syndrome and autism
32. The prevalence of language delay in a population of three-year old children and its association with general retardation
33. Prevalence of specific language impairment in kindergarten children
34. Neonatal hypoglycemia and withdrawal symptoms after exposure in utero to valproate
35. Adverse neurodevelopmental outcome of moderate neonatal hypoglycaemia
36. Ophthalmic findings in fetal anticonvulsant syndrome(s)
37. Fetal valproate syndrome
38. Prenatal exposure to phenytoin, facial development, and a possible role for vitamin K
39. Homocysteine concentrations and methionine loading in patients on antiepileptic drugs
40. Alteration of embryonic folate metabolism by valproic acid during organogenesis: Implications for mechanism of teratogenesis
41. Impaired methionine synthesis and hypomethylation in rats exposed to valproate during gestation
42. Mutated methylenetetrahydrofolate reductase as a risk factor For spina bifida
43. 5,10 Methylenetatrahydrofolate reductase gene variants and congenital anomalies: A HuGE review
44. Occurrence of congenital heart defects in relation to maternal multivitamin use
45. Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene
46. Folic acid antagonists during pregnancy and the risk of birth defects
47. Marked accumulation of valproic acid in embryonic neuroepithelium of the mouse during early organogenesis
48. Valproate-induced limb malformations in mice associated with reduction of intracellular pH
49. Prenatal prediction of risk of the fetal hydantoin syndrome
50. Phenytoin-induced teratogenesis: A molecular basis for the observed developmental delay during neurulation
51. A mouse model for valproate teratogenicity: Parental effects, homeotic transformations, and altered HOX expression
52. Developmental toxicity of valproic acid during embryonic chick vertebral chondrogenesis